2025 Q4 -tulosraportti
Vain PDF
68 päivää sitten
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 500 | AVA | NON | ||
| 9 000 | SHB | ENS | ||
| 668 | SHB | AVA | ||
| 438 | SSWM | NON | ||
| 5 | ENS | ENS |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Svenska Handelsbanken AB | 9 668 | 0 | +9 668 | 0 |
| Avanza Bank AB | 1 500 | 668 | +832 | 0 |
| SSW Market Making GmbH | 438 | 0 | +438 | 0 |
| Nordnet Bank AB | 0 | 1 938 | −1 938 | 0 |
| Skandinaviska Enskilda Banken AB | 5 | 9 005 | −9 000 | 5 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Skandinaviska Enskilda Banken AB | 5 | 9 005 | −9 000 | 5 |
| Nordnet Bank AB | 0 | 1 938 | −1 938 | 0 |
| SSW Market Making GmbH | 438 | 0 | +438 | 0 |
| Avanza Bank AB | 1 500 | 668 | +832 | 0 |
| Svenska Handelsbanken AB | 9 668 | 0 | +9 668 | 0 |
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 20.2. | ||
2025 Q3 -tulosraportti 7.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 21.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·23.1. · MuokattuWith Q4 2025 growth, Bio-W stock should reach at least 6kr during 2026.
·25.10.2025Good then. Continue with your philanthropy..
·1.12.2025What exactly is the problem then..? Please be specific..since you seem to know things…?
·8.9.2025There is no better track record in management and board. Peter von Ehrenheim has an operational background from Pharmacia, and GE Healthcare. He was general manager for Separations Division 1999-2006, and from 2006-2011, general manager for GE’s Life Sciences business which was acquired by Danaher in 2020. Peter Nählstedt has more than 20 years of operational experience from leading positions in life science and industry. His experience includes CEO of Probi AB (publ), Director Europe Trelleborg Marine Systems and General Manager North America BioProcess at GE Healthcare. The owner, Staffan Persson, is an investor oracle.- ·8.9.2025Their USP is higher binding capacity even in fast purification processes, 92% purity compared to GE's 85% according to their investor presentations. Their separation media has higher resistance to cleaning between process cycles, which leads to longer durability which means lower TCO and higher ROI for the customer. The product captures 30% more target molecule & output at high flow compared to their main competitor GE. In PoV they have shown 7% more efficiency than GE which increased the customer's turnover by 100 SEKm per production cycle.¨
- ·8.9.2025Authorities require that the same separation media used in Phase 3 are also used in full production for FDA/EMA approval. Thus, Bio-Works' customer pipeline means a guaranteed exponential revenue curve. However, purchase volumes of separation media are relatively low in Phase 1 and 2 during customers' drug development. Bio-Works is unique with such a business model of exceptionally high stickiness and exponential revenue curve from secured customer contracts. But it is a long-term case.
·1.10.2025Agree - it was precisely that model that caught my eye. Their press releases regarding orders are difficult to interpret and evaluate. It is not clear whether it is a new project, additional order, early order; in short, what the order actually means for BW. It has been a long time since they published news about an order. A bit worrying.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
68 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·23.1. · MuokattuWith Q4 2025 growth, Bio-W stock should reach at least 6kr during 2026.
- ·25.10.2025Good then. Continue with your philanthropy..·1.12.2025What exactly is the problem then..? Please be specific..since you seem to know things…?
- ·8.9.2025There is no better track record in management and board. Peter von Ehrenheim has an operational background from Pharmacia, and GE Healthcare. He was general manager for Separations Division 1999-2006, and from 2006-2011, general manager for GE’s Life Sciences business which was acquired by Danaher in 2020. Peter Nählstedt has more than 20 years of operational experience from leading positions in life science and industry. His experience includes CEO of Probi AB (publ), Director Europe Trelleborg Marine Systems and General Manager North America BioProcess at GE Healthcare. The owner, Staffan Persson, is an investor oracle.
- ·8.9.2025Their USP is higher binding capacity even in fast purification processes, 92% purity compared to GE's 85% according to their investor presentations. Their separation media has higher resistance to cleaning between process cycles, which leads to longer durability which means lower TCO and higher ROI for the customer. The product captures 30% more target molecule & output at high flow compared to their main competitor GE. In PoV they have shown 7% more efficiency than GE which increased the customer's turnover by 100 SEKm per production cycle.¨
- ·8.9.2025Authorities require that the same separation media used in Phase 3 are also used in full production for FDA/EMA approval. Thus, Bio-Works' customer pipeline means a guaranteed exponential revenue curve. However, purchase volumes of separation media are relatively low in Phase 1 and 2 during customers' drug development. Bio-Works is unique with such a business model of exceptionally high stickiness and exponential revenue curve from secured customer contracts. But it is a long-term case.·1.10.2025Agree - it was precisely that model that caught my eye. Their press releases regarding orders are difficult to interpret and evaluate. It is not clear whether it is a new project, additional order, early order; in short, what the order actually means for BW. It has been a long time since they published news about an order. A bit worrying.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 500 | AVA | NON | ||
| 9 000 | SHB | ENS | ||
| 668 | SHB | AVA | ||
| 438 | SSWM | NON | ||
| 5 | ENS | ENS |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Svenska Handelsbanken AB | 9 668 | 0 | +9 668 | 0 |
| Avanza Bank AB | 1 500 | 668 | +832 | 0 |
| SSW Market Making GmbH | 438 | 0 | +438 | 0 |
| Nordnet Bank AB | 0 | 1 938 | −1 938 | 0 |
| Skandinaviska Enskilda Banken AB | 5 | 9 005 | −9 000 | 5 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Skandinaviska Enskilda Banken AB | 5 | 9 005 | −9 000 | 5 |
| Nordnet Bank AB | 0 | 1 938 | −1 938 | 0 |
| SSW Market Making GmbH | 438 | 0 | +438 | 0 |
| Avanza Bank AB | 1 500 | 668 | +832 | 0 |
| Svenska Handelsbanken AB | 9 668 | 0 | +9 668 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 20.2. | ||
2025 Q3 -tulosraportti 7.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 21.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
68 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 20.2. | ||
2025 Q3 -tulosraportti 7.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 21.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·23.1. · MuokattuWith Q4 2025 growth, Bio-W stock should reach at least 6kr during 2026.
- ·25.10.2025Good then. Continue with your philanthropy..·1.12.2025What exactly is the problem then..? Please be specific..since you seem to know things…?
- ·8.9.2025There is no better track record in management and board. Peter von Ehrenheim has an operational background from Pharmacia, and GE Healthcare. He was general manager for Separations Division 1999-2006, and from 2006-2011, general manager for GE’s Life Sciences business which was acquired by Danaher in 2020. Peter Nählstedt has more than 20 years of operational experience from leading positions in life science and industry. His experience includes CEO of Probi AB (publ), Director Europe Trelleborg Marine Systems and General Manager North America BioProcess at GE Healthcare. The owner, Staffan Persson, is an investor oracle.
- ·8.9.2025Their USP is higher binding capacity even in fast purification processes, 92% purity compared to GE's 85% according to their investor presentations. Their separation media has higher resistance to cleaning between process cycles, which leads to longer durability which means lower TCO and higher ROI for the customer. The product captures 30% more target molecule & output at high flow compared to their main competitor GE. In PoV they have shown 7% more efficiency than GE which increased the customer's turnover by 100 SEKm per production cycle.¨
- ·8.9.2025Authorities require that the same separation media used in Phase 3 are also used in full production for FDA/EMA approval. Thus, Bio-Works' customer pipeline means a guaranteed exponential revenue curve. However, purchase volumes of separation media are relatively low in Phase 1 and 2 during customers' drug development. Bio-Works is unique with such a business model of exceptionally high stickiness and exponential revenue curve from secured customer contracts. But it is a long-term case.·1.10.2025Agree - it was precisely that model that caught my eye. Their press releases regarding orders are difficult to interpret and evaluate. It is not clear whether it is a new project, additional order, early order; in short, what the order actually means for BW. It has been a long time since they published news about an order. A bit worrying.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 500 | AVA | NON | ||
| 9 000 | SHB | ENS | ||
| 668 | SHB | AVA | ||
| 438 | SSWM | NON | ||
| 5 | ENS | ENS |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Svenska Handelsbanken AB | 9 668 | 0 | +9 668 | 0 |
| Avanza Bank AB | 1 500 | 668 | +832 | 0 |
| SSW Market Making GmbH | 438 | 0 | +438 | 0 |
| Nordnet Bank AB | 0 | 1 938 | −1 938 | 0 |
| Skandinaviska Enskilda Banken AB | 5 | 9 005 | −9 000 | 5 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Skandinaviska Enskilda Banken AB | 5 | 9 005 | −9 000 | 5 |
| Nordnet Bank AB | 0 | 1 938 | −1 938 | 0 |
| SSW Market Making GmbH | 438 | 0 | +438 | 0 |
| Avanza Bank AB | 1 500 | 668 | +832 | 0 |
| Svenska Handelsbanken AB | 9 668 | 0 | +9 668 | 0 |